Patents by Inventor Shari A. Pilon-Thomas
Shari A. Pilon-Thomas has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240156910Abstract: In one aspect, disclosed herein are methods of expanding tumor infiltrating lymphocytes (TILs) in vitro or ex vivo comprising obtaining TILs and culturing the TILs in media comprising one or more CD40 agonists (such as, for example, a CD40 ligand (CD40L) and/or anti-CD40 antibody).Type: ApplicationFiled: March 16, 2022Publication date: May 16, 2024Inventors: Daniel ABATE DAGA, Shari PILON-THOMAS, Renata Marques ROSSETTI, Matthew BEATTY
-
Publication number: 20240041972Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: ApplicationFiled: April 3, 2023Publication date: February 8, 2024Inventors: Mark MCLAUGHLIN, David L. MORSE, Shari Pilon-Thomas, Scott Antonia
-
Patent number: 11518980Abstract: Disclosed are compositions and methods for ex vivo expansion of tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor-infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.Type: GrantFiled: February 11, 2019Date of Patent: December 6, 2022Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South FloridaInventors: Amod A. Sarnaik, Shari Pilon-Thomas, Mark McLaughlin, Hao Liu
-
Publication number: 20220340874Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.Type: ApplicationFiled: June 28, 2022Publication date: October 27, 2022Inventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule, MacLean S. Hall
-
Publication number: 20220282215Abstract: Disclosed are compositions and methods for ex vivo expansion of tumorinfiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumorinfiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.Type: ApplicationFiled: May 24, 2022Publication date: September 8, 2022Inventors: Amod A. Sarnaik, Shari Pilon-Thomas, Mark McLaughlin, Hao Liu
-
Patent number: 11401506Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.Type: GrantFiled: December 20, 2018Date of Patent: August 2, 2022Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., Board nf Regents The Inivercitvof Texas CvctomInventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule, MacLean S. Hall
-
Publication number: 20220002673Abstract: Tumor infiltrating lymphocytes (TILs) are immune cells that have left the bloodstream and migrated into a tumor. TILs have been used in autologous adoptive transfer therapy for the treatment of cancer. Disclosed are methods for rapidly expanding tumor infiltrating lymphocytes using digested tumor cells.Type: ApplicationFiled: September 24, 2019Publication date: January 6, 2022Inventors: John Ellis MULLINAX, Shari PILON-THOMAS, Amod SARNAIK
-
Publication number: 20200377855Abstract: Disclosed are methods for rapidly expanding tumor infiltrating lymphocytes.Type: ApplicationFiled: May 4, 2018Publication date: December 3, 2020Inventors: Linda L. Kelley, Nermin Gerges, John Ellis Mullinax, Shari Pilon-Thomas, Amod Ashok Sarniak, MacLean Scott Hall
-
Publication number: 20200188472Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: ApplicationFiled: October 21, 2019Publication date: June 18, 2020Inventors: Mark MCLAUGHLIN, David L. MORSE, Shari Pilon-Thomas, Scott Antonia
-
Publication number: 20200032209Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.Type: ApplicationFiled: December 20, 2018Publication date: January 30, 2020Inventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule, MacLean S. Hall
-
Patent number: 10449227Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: GrantFiled: June 26, 2015Date of Patent: October 22, 2019Assignees: H. Lee Moffitt Cancer Center and Research Institute, Inc., University of South FloridaInventors: Mark McLaughlin, David L. Morse, Shari Pilon-Thomas, Scott Antonia
-
Publication number: 20190177693Abstract: Disclosed are compositions and methods for ex vivo expansion of tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumor-infiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.Type: ApplicationFiled: February 11, 2019Publication date: June 13, 2019Inventors: Amod A. Sarnaik, Shari Pilon-Thomas, Mark McLaughlin, Hao Liu
-
Patent number: 10130658Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.Type: GrantFiled: December 18, 2015Date of Patent: November 20, 2018Assignees: Provectus Pharmatech, Inc., H. Lee Moffitt Cancer Center and Research Institute, Inc.Inventors: Jamie Singer, Eric Wachter, Amod Sarnaik, Shari Pilon-Thomas, Hao Liu
-
Publication number: 20170202902Abstract: The current invention pertains to a molecular conjugate comprising an antagonist of a cell surface receptor specific to a target cell and an immune effector, such as a T cell modulator, conjugated to the antagonist. The target cell can be a cell responsible for development of a disease in a subject, for example, a cancer cell. In certain embodiments, the immune effector is an immune effector protein or an immune effector fragment thereof. The current invention also pertains to a method of treating a disease in a subject, the method comprising administering to the subject a pharmaceutically effective amount of the molecular conjugates of the current invention to the subject. The methods of the current invention can be used to treat cancer, such as breast cancer, ovarian cancer, prostate cancer, lung cancer, pancreatic cancer, or melanoma.Type: ApplicationFiled: June 26, 2015Publication date: July 20, 2017Inventors: Mark MCLAUGHLIN, David L. MORSE, Shari PILON-THOMAS, Scott ANTONIA
-
Publication number: 20170173079Abstract: A cancer immunotherapy method is disclosed in which “induced immune anticancer agents” are isolated after being induced in an animal host by intralesional (IL) administration of a halogenated xanthene tumor-ablative compound into a solid cancerous tumor of that host animal. A sample of the induced immune anticancer agents is removed (collected) from the tumor-bearing host, banked if desired, cultured and preferentially expanded to form an immunologically-effective enriched tumor-specific immune anticancer agent composition. That composition is reintroduced in to the host from which the predecessor induced immune anticancer agents were taken, or into another immunologically suitable host in need.Type: ApplicationFiled: December 18, 2015Publication date: June 22, 2017Applicant: PROVECTUS PHARMATECH, INC.Inventors: Jamie Singer, Eric Wachter, Amod Sarnaik, Shari Pilon-Thomas, Hao Liu
-
Publication number: 20170081635Abstract: Disclosed are compositions and methods for ex vivo expansion of tumorinfiltrating lymphocytes for use in adoptive cell therapy (ACT). Also disclosed are compositions and method for identifying an agent for ex vivo expansion of tumorinfiltrating lymphocytes for use in ACT. Also disclosed are methods for treating cancer using tumor-infiltrating lymphocytes expanded by the disclosed methods.Type: ApplicationFiled: March 20, 2015Publication date: March 23, 2017Inventors: Amod A. Sarnaik, Shari Pilon-Thomas, Mark McLaughlin, Hao Liu
-
Publication number: 20170044496Abstract: Disclosed herein is a method for ex vivo expanding tumor-infiltrating lymphocytes for use in adoptive cell therapy (ACT). The method involves culturing tumor fragments from the subject in a culture medium containing IL-2 and a 41BB agonist in an amount effective to expand tumor-infiltrating lymphocytes with enriched tumor-reactivity and specificity. Also disclosed is a method for treating a tumor in a subject that involves treating the subject with nonmyeloablative lymphodepleting chemotherapy, and administering tumor-infiltrating lymphocytes expanded by the disclosed methods.Type: ApplicationFiled: April 10, 2015Publication date: February 16, 2017Inventors: Amod A. Sarnaik, Jeffrey S. Weber, Shari Pilon-Thomas, Laszlo G. Radvanyi, Jessica Ann Chacon, James J. Mule'
-
Patent number: 8597946Abstract: Described herein are methods of cancer immunotherapy, particularly methods of preparing a population of enhanced dendritic cells and methods of treating cancer using the enhanced dendritic cells.Type: GrantFiled: March 10, 2009Date of Patent: December 3, 2013Assignees: H. Lee Moffitt Caner Center and Research Institute, Inc., The Regents of the University of MichiganInventors: James J. Mule, Shari A. Pilon-Thomas, Norimasa Matsushita, Annabelle Grolleau-Julius
-
Publication number: 20110059054Abstract: Described herein are methods of cancer immunotherapy, particularly methods of preparing a population of enhanced dendritic cells and methods of treating cancer using the enhanced dendritic cells.Type: ApplicationFiled: March 10, 2009Publication date: March 10, 2011Applicant: THE REGENTS OF THE UNIVERSITY OF MICHIGANInventors: James J. Mule, Shari A. Pilon-Thomas, Norimasa Matsushita, Annabelle Grolleau-Julius